Aarkstore Enterprise - Idiopathic Pulmonary Fibrosis - Pipeline Assessment And Market Forecasts

Aarkstore announce a new report "Idiopathic Pulmonary Fibrosis - Pipeline Assessment

and Market Forecasts to 2017 " through its vast collection of market reserach report.

Summary

Pharmaceutical and healthcare report, Idiopathic Pulmonary Fibrosis - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. The report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis team of industry experts.

The global Idiopathic Pulmonary Fibrosis (IPF) market was valued at $88m in 2009. It is expected to increase with a compound annual growth rate (CAGR) of 23% from $88m in 2009 to $462m by 2017. Earlier, the IPF market was underserved due to a lack of approved products. In October 2008, the Japanese manufacturer Shionogi received approval for Pirespa in Japan. It is under regulatory review for approval in the US and EU. The expected increase in sales is due to the expected approval of Pirespa in the US and the EU and also the expected launch of Tracleer and Letiaris. Growth in the IPF market is being driven by the sales of Pirespa, off-label drug use and the anticipated approval of Letiaris and Tracleer. Gileads Letiaris and Actelions Tracleer are the most anticipated molecules in the IPF market.

Scope

The report provides information on the key driver and challenges of the idiopathic pulmonary fibrosis market. Its scope includes:

- Annualized global idiopathic pulmonary fibrosis market revenues data from 2001 to 2009, forecast forward for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include enzyme inhibitors, protein inhibitors, endothelin A antagonists, combination therapy, TNF alpha antagonists, platelet aggregation inhibitors, interferon alpha, interleukin inhibitors, immunosuppresants, growth hormone inhibitors, gene therapy, LPA1 receptor antagonists, tumor growth factor inhibitors and NK-1 antagonists.

- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key market players covered are Gilead Sciences, Actelion Ltd., Amgen Inc., InterMune Inc. and Amarillo Biosciences.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with idiopathic pulmonary fibrosis therapeutics.

For more information, please visit:

http://www.aarkstore.com/reports/Idiopathic-Pulmonary-Fibrosis-Pipeline-Assessment-and-Market-Forecasts-to-2017-39100.html

Or email us at press@aarkstore.com or call +919272852585

by: Aarkstore Enterprise

POST COMMENT

Use Facebook to Market Your Company Investing In Banner Stand Marketing Israel In Vitro Diagnostics Market Outlook to 2016 A Comprehensive Guide To Medical Marketing World Wide Web Advertising and Marketing Online System 2009 Clothing Market- Ed Hardy Dental Care Proves To Be Effective In Condo Marketing Textile Market – Producing Exquisite Work of Quality Aarkstore Enterprise - Neuropathic Pain - Pipeline Assessment And Market Forecasts To 2016 Google Nexus One Deals: The Best Is Now Out In The Market Permission Email Marketing - How to Prepopulate CPA Offers With Aweber Easy Backup Wizard Scam Market News Giving Shape To Investment Goals